Home | Regulatory Tracker | Semax
Semax
PCAC recommended
as of October 2026
By Stephen Kimball, 26+ years researching the health, wellness, supplement, and peptide industries
As of October 2026, Semax isn’t approved for any use in the U.S. and isn’t on the list of ingredients pharmacies may compound with. It left FDA’s safety-risk list in April 2026 because its nominators withdrew, not because FDA cleared it. FDA’s page still says the agency has little or no safety information for the proposed routes. In July 2026, an advisory panel reportedly voted 8–5, with one abstention, to recommend adding it, even though FDA’s own reviewers advised against it. That vote is advice only; nothing changes until FDA proposes and finalizes a rule. Today it’s sold mainly by “research use only” sites, with no FDA oversight of what’s in the vial.
Sources
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (withdrawn table)
U.S. Food & Drug Administration
dated Apr 2026
FDA Briefing Document — Semax-Related Bulk Drug Substances
U.S. Food & Drug Administration
dated Jul 2026
Change log
2023
FDA places Semax in Category 2.
April 2026
Moves to FDA’s “nominated but withdrawn” table after nominators withdraw; FDA’s safety note stays listed.
July 2026
FDA staff briefing proposes that Semax NOT be added.
July 24, 2026
Advisory panel reportedly votes 8–5 (1 abstention) to recommend adding Semax, for cerebral ischemia, migraine, and trigeminal neuralgia.